Table 4.
The relationship between Scottish Inflammatory Prognostic Score (SIPS) and progression-free survival and overall survival at 3 months, 6 months, and 12 months in patients with non-small-cell lung cancer receiving first-line pembrolizumab monotherapy: P < 0.001 log rank
| SIPS | Patients [n (%)] | Median (IQR) months | P | Survival at 3 months [n (%)] | Survival at 6 months [n (%)] | Survival at 12 months [n (%)] | |
|---|---|---|---|---|---|---|---|
| PFS | 0 | 74 (34) | 17.9 (6.0-50.4) | <0.001 | 64 (86) | 56 (76) | 31 (42) |
| 1 | 67 (31) | 8.7 (2.6-22.5) | 46 (68) | 38 (57) | 25 (37) | ||
| 2 | 78 (36) | 2.5 (1.3-7.5) | 36 (46) | 24 (31) | 12 (15) | ||
| OS | 0 | 74 (34) | 28.7 (11.0-n/r) | <0.001 | 69 (93) | 68 (92) | 41 (55) |
| 1 | 67 (31) | 12.4 (4.7-n/r) | 55 (82) | 47 (70) | 30 (45) | ||
| 2 | 78 (36) | 5.1 (1.9-11.7) | 48 (62) | 36 (46) | 18 (23) |
Italic values are statistically significant.
IQR, interquartile range; n/r = not reached; OS, overall survival; PFS, progression-free survival.